{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:38:24Z","timestamp":1775043504969,"version":"3.50.1"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1307604"],"award-info":[{"award-number":["2024YFA1307604"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["8247082356"],"award-info":[{"award-number":["8247082356"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09157-3","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:24:20Z","timestamp":1775031860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Biomarkers and Therapeutic Targets for Idiopathic Inflammatory Myopathies Related Lung Disease"],"prefix":"10.1007","volume":"69","author":[{"given":"Hongzheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shulan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"11","key":"9157_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","volume":"19","author":"T Khoo","year":"2023","unstructured":"Khoo T, Lilleker JB, Thong BY et al (2023) Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol 19(11):695\u2013712","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"9157_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","volume":"194","author":"C Johnson","year":"2016","unstructured":"Johnson C, Pinal-Fernandez I, Parikh R et al (2016) Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194(5):733\u20137","journal-title":"Lung"},{"issue":"1","key":"9157_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","volume":"51","author":"Y SUN K Y, FAN","year":"2021","unstructured":"Sun K Y, Fan Y, Wang Y X et al (2021) Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020 [J]. Semin Arthritis Rheum 51(1):175\u2013191","journal-title":"Semin Arthritis Rheum"},{"key":"9157_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejim.2021.12.021","volume":"97","author":"P Decker","year":"2022","unstructured":"Decker P, Sobanski V, Moulinet T et al (2022) Interstitial pneumonia with autoimmune features: evaluation of connective tissue disease incidence during follow-up. Eur J Intern Med 97:62\u20138","journal-title":"Eur J Intern Med"},{"issue":"1","key":"9157_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.31138\/mjr.180324.dtc","volume":"36","author":"I Mb","year":"2025","unstructured":"Mb I, Deepak D, Bhatta A et al (2025) Prevalence of anti-synthetase syndrome in patients of interstitial lung disease with connective tissue diseases and autoimmune features: a cross-sectional study. Mediterr J Rheumatol 36(1):107\u201315","journal-title":"Mediterr J Rheumatol"},{"key":"9157_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.rmed.2017.03.028","volume":"132","author":"CA SCIR\u00e8","year":"2017","unstructured":"SCIR\u00e8 CA, Gonzalez-Gay MA, Selva-O\u2019callaghan A et al (2017) Clinical spectrum time course of interstitial pneumonia with autoimmune features in patients positive for antisynthetase antibodies. Respir Med 132:265\u20136","journal-title":"Respir Med"},{"issue":"2","key":"9157_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1378\/chest.10-0194","volume":"138","author":"A FISCHER","year":"2010","unstructured":"Fischer A, West S G Swigrisjj et al (2010) Connective tissue disease-associated interstitial lung disease: a call for clarification [J]. Chest 138(2):251\u2013256","journal-title":"Chest"},{"issue":"7","key":"9157_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1164\/rccm.200702-220OC","volume":"176","author":"BW Kinder","year":"2007","unstructured":"Kinder BW, Collard HR, Koth L et al (2007) Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 176(7):691\u20137","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"9157_CR9","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1378\/chest.10-2662","volume":"140","author":"R Vij","year":"2011","unstructured":"Vij R, Noth I, Strek ME (2011) Autoimmune-featured interstitial lung disease: a distinct entity. Chest 140(5):1292\u20139","journal-title":"Chest"},{"issue":"4","key":"9157_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer A, Antoniou KM, Brown KK et al (2015) An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46(4):976\u201387","journal-title":"Eur Respir J"},{"issue":"6","key":"9157_CR11","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","volume":"163","author":"RW Hallowell","year":"2023","unstructured":"Hallowell RW, Danoff SK (2023) Diagnosis and management of myositis-associated lung disease. Chest 163(6):1476\u201391","journal-title":"Chest"},{"issue":"1","key":"9157_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","volume":"77","author":"JB Lilleker","year":"2018","unstructured":"Lilleker JB, Vencovsky J, Wang G et al (2018) The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 77(1):30\u20139","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"9157_CR13","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1183\/09031936.00156312","volume":"42","author":"B Hervier","year":"2013","unstructured":"Hervier B, Meyer A, Dieval C et al (2013) Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J 42(5):1271\u201382","journal-title":"Eur Respir J"},{"issue":"10","key":"9157_CR14","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/rheumatology\/kes167","volume":"51","author":"F CHUA","year":"2012","unstructured":"Chua F, Higton A M, Colebatch A N et al (2012) Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort [J]. Rheumatology (Oxford) 51(10):1870\u20131876","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"9157_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","volume":"56","author":"JA PINAL-FERNANDEZ I, CASAL-DOMINGUEZ","year":"2017","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA et al (2017) A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies [J]. Rheumatology (Oxford) 56(6):999\u20131007","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"9157_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","volume":"60","author":"W Wu","year":"2021","unstructured":"Wu W, Guo L, Fu Y et al (2021) Interstitial lung disease in anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol 60(2):293\u2013304","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"9157_CR17","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z CHEN","year":"2013","unstructured":"Chen Z, Cao M, Plana M N et al (2013) Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis [J]. Arthritis Care Res (Hoboken) 65(8):1316\u20131324","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"9157_CR18","first-page":"891","volume":"32","author":"A CERIBELLI","year":"2014","unstructured":"Ceribelli A, Fredi M, Taraborelli M et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis [J]. Clin Exp Rheumatol 32(6):891\u2013897","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"9157_CR19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/acr.21895","volume":"65","author":"I MARIE","year":"2013","unstructured":"Marie I, Josse S, Hatron P Y et al (2013) Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome [J]. Arthritis Care Res (Hoboken) 65(5):800\u2013808","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"9157_CR20","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T GONO","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis [J]. Rheumatology (Oxford) 51(9):1563\u20131570","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"9157_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T KOGA","year":"2012","unstructured":"Koga T, Fujikawa K, Horai Y et al (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM [J]. Rheumatology (Oxford) 51(7):1278\u20131284","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"9157_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y et al (2020) Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72(3):488\u201398","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"9157_CR23","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/rheumatology\/keac525","volume":"62","author":"X LIAN","year":"2023","unstructured":"Lian X, Ye Y, Zou J et al (2023) Longitudinal study of patients with antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease [J]. Rheumatology (Oxford) 62(5):1910\u20131919","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"9157_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1620\/tjem.239.297","volume":"239","author":"F Tomiyama","year":"2016","unstructured":"Tomiyama F, Watanabe R, Ishii T et al (2016) High prevalence of acute exacerbation of interstitial lung disease in Japanese patients with systemic sclerosis. Tohoku J Exp Med 239(4):297\u2013305","journal-title":"Tohoku J Exp Med"},{"issue":"6","key":"9157_CR25","doi-asserted-by":"publisher","first-page":"R214","DOI":"10.1186\/ar3547","volume":"13","author":"Y MURO","year":"2011","unstructured":"Muro Y, Sugiura K, Hoshino K et al (2011) Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan [J]. Arthritis Res Ther 13(6):R214","journal-title":"Arthritis Res Ther"},{"key":"9157_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001202","author":"N Nishina","year":"2020","unstructured":"Nishina N, Sato S, Masui K et al (2020) Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2020-001202","journal-title":"RMD Open"},{"key":"9157_CR27","doi-asserted-by":"publisher","first-page":"837024","DOI":"10.3389\/fmed.2022.837024","volume":"9","author":"H SO","year":"2022","unstructured":"So H, So J, Lam T T et al (2022) Seasonal Effect on Disease Onset and Presentation in Anti-MDA5 Positive Dermatomyositis [J]. Front Med (Lausanne) 9:837024","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"9157_CR28","doi-asserted-by":"publisher","first-page":"102788","DOI":"10.1016\/j.autrev.2021.102788","volume":"20","author":"S TOQUET","year":"2021","unstructured":"Toquet S, Granger B, Uzunhan Y et al (2021) The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger [J]. Autoimmun Rev 20(4):102788","journal-title":"Autoimmun Rev"},{"key":"9157_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791348","volume":"12","author":"G Wang","year":"2021","unstructured":"Wang G, Wang Q, Wang Y et al (2021) Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front Immunol 12:791348","journal-title":"Front Immunol"},{"issue":"1","key":"9157_CR30","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1038\/s41467-021-25509-3","volume":"12","author":"SE CHANG","year":"2021","unstructured":"Chang Se, Feng A, Meng W et al (2021) New-onset IgG autoantibodies in hospitalized patients with COVID-19 [J]. Nat Commun 12(1):5417","journal-title":"Nat Commun"},{"issue":"1","key":"9157_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s42399-022-01357-0","volume":"5","author":"S WANG","year":"2023","unstructured":"Wang S, Noumi B, Malik F et al (2023) A Rare Case of MDA-5-Positive Amyopathic Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Following COVID-19 mRNA Vaccination - a Case Report [J]. SN Compr Clin Med 5(1):18","journal-title":"SN Compr Clin Med"},{"issue":"12","key":"9157_CR32","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s00296-022-05176-3","volume":"42","author":"M HOLZER M T, KRUSCHE","year":"2022","unstructured":"Holzer M T, Krusche M, Ruffer N et al (2022) New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review [J]. Rheumatol Int 42(12):2267\u20132276","journal-title":"Rheumatol Int"},{"key":"9157_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1565803","volume":"16","author":"S Lattarulo","year":"2025","unstructured":"Lattarulo S, Centrone F, Chironna M (2025) Anti-MDA5\u2009+\u2009dermatomyositis following SARS-COV-2 infections: a systematic review. Front Immunol 16:1565803","journal-title":"Front Immunol"},{"issue":"8","key":"9157_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11926-021-01023-9","volume":"23","author":"A Saud","year":"2021","unstructured":"Saud A, Naveen R, Aggarwal R et al (2021) COVID-19 and myositis: what we know so far. Curr Rheumatol Rep 23(8):63","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"9157_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218594","volume":"81","author":"Y Wang","year":"2022","unstructured":"Wang Y, Du G, Zhang G et al (2022) Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. Ann Rheum Dis 81(10):e192","journal-title":"Ann Rheum Dis"},{"key":"9157_CR36","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01618-2020","author":"M Giannini","year":"2020","unstructured":"Giannini M, Ohana M, Nespola B et al (2020) Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01618-2020","journal-title":"Eur Respir J"},{"key":"9157_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105136","volume":"104","author":"P David","year":"2024","unstructured":"David P, Sinha S, Iqbal K et al (2024) MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). EBioMedicine 104:105136","journal-title":"EBioMedicine"},{"key":"9157_CR38","doi-asserted-by":"publisher","first-page":"103390","DOI":"10.1016\/j.ebiom.2021.103390","volume":"68","author":"SAHOOD KATKAR G D","year":"2021","unstructured":"Katkar G D Sahood (2021) AI-guided discovery of the invariant host response to viral pandemics [J]. EBioMedicine 68:103390","journal-title":"EBioMedicine"},{"issue":"2","key":"9157_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/joim.13154","volume":"289","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Koga T, Furukawa K et al (2021) IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis\/dermatomyositis. J Intern Med 289(2):206\u201320","journal-title":"J Intern Med"},{"issue":"9","key":"9157_CR40","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3899\/jrheum.170165","volume":"44","author":"Z Chen","year":"2017","unstructured":"Chen Z, Wang Y, Kuwana M et al (2017) HLA-DRB1 alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis. J Rheumatol 44(9):1389\u201393","journal-title":"J Rheumatol"},{"issue":"7","key":"9157_CR41","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","volume":"78","author":"S Rothwell","year":"2019","unstructured":"Rothwell S, Chinoy H, Lamb JA et al (2019) Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 78(7):996\u20131002","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"9157_CR42","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/annrheumdis-2017-212149","volume":"77","author":"Y KOCHI","year":"2018","unstructured":"Kochi Y, Kamatani Y, Kondo Y et al (2018) Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis [J]. Ann Rheum Dis 77(4):602\u2013611","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9157_CR43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12931-023-02362-0","volume":"24","author":"Y ZAIZEN","year":"2023","unstructured":"Zaizen Y, Okamoto M, Azuma K et al (2023) Enhanced immune complex formation in the lungs of patients with dermatomyositis [J]. Respir Res 24(1):86","journal-title":"Respir Res"},{"issue":"1","key":"9157_CR44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/keac234","volume":"62","author":"N SHEN","year":"2022","unstructured":"Shen N, Zhou X, Jin X et al (2022) MDA5 expression is associated with TGF-\u03b2-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis [J]. Rheumatology (Oxford) 62(1):373\u2013383","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"9157_CR45","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bjd.16917","volume":"180","author":"SH ZHANG","year":"2019","unstructured":"Zhang SH, Zhao Y, Xie Q B et al (2019) Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis [J]. Br J Dermatol 180(5):1090\u20131098","journal-title":"Br J Dermatol"},{"issue":"10","key":"9157_CR46","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1136\/annrheumdis-2020-217522","volume":"79","author":"S MEGREMIS","year":"2020","unstructured":"Megremis S, Walker T D J, He X et al (2020) Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis [J]. Ann Rheum Dis 79(10):1383\u20131386","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9157_CR47","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y YE","year":"2022","unstructured":"Ye Y, Chen Z (2022) Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5\u2009+\u2009dermatomyositis with therapeutic implications [J]. Nat Commun 13(1):6458","journal-title":"Nat Commun"},{"key":"9157_CR48","doi-asserted-by":"publisher","first-page":"743704","DOI":"10.3389\/fimmu.2021.743704","volume":"12","author":"K WANG","year":"2021","unstructured":"Wang K, Zhao J, Wu W et al (2021) RNA-Containing Immune Complexes Formed by Anti-Melanoma Differentiation Associated Gene 5 Autoantibody Are Potent Inducers of IFN-\u03b1 [J]. Front Immunol 12:743704","journal-title":"Front Immunol"},{"issue":"1","key":"9157_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13075-018-1737-2","volume":"20","author":"Y ISHIKAWA","year":"2018","unstructured":"Ishikawa Y, Iwata S, Hanami K et al (2018) Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis [J]. Arthritis Res Ther 20(1):240","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"9157_CR50","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","volume":"14","author":"G LE BON A, SCHIAVONI","year":"2001","unstructured":"Le Bon A, Schiavoni G, D\u2019agostino G et al (2001) Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo [J]. Immunity 14(4):461\u2013470","journal-title":"Immunity"},{"issue":"2","key":"9157_CR51","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1074-7613(03)00208-5","volume":"19","author":"G Jego","year":"2003","unstructured":"Jego G, Palucka AK, Blanck JP et al (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19(2):225\u201334","journal-title":"Immunity"},{"issue":"5","key":"9157_CR52","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20050821","volume":"202","author":"THOMASS KOLUMAM G A","year":"2005","unstructured":"Kolumam G A Thomass, Thompson L J et al (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection [J]. J Exp Med 202(5):637\u2013650","journal-title":"J Exp Med"},{"issue":"9","key":"9157_CR53","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.rmed.2015.07.004","volume":"109","author":"T Takada","year":"2015","unstructured":"Takada T, Aoki A, Asakawa K et al (2015) Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis. Respir Med 109(9):1174\u201380","journal-title":"Respir Med"},{"issue":"2","key":"9157_CR54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.trsl.2010.11.007","volume":"157","author":"T ISOZAKI","year":"2011","unstructured":"Isozaki T, Otsuka K, Sato M et al (2011) Synergistic induction of CX3CL1 by interleukin-1\u03b2 and interferon-\u03b3 in human lung fibroblasts: involvement of signal transducer and activator of transcription 1 signaling pathways [J]. Transl Res 157(2):64\u201370","journal-title":"Transl Res"},{"issue":"1","key":"9157_CR55","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2249.2012.04638.x","volume":"170","author":"M Nakano","year":"2012","unstructured":"Nakano M, Fujii T, Hashimoto M et al (2012) Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells. Clin Exp Immunol 170(1):94\u2013100","journal-title":"Clin Exp Immunol"},{"key":"9157_CR56","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00460-2019","author":"FR Greiffo","year":"2020","unstructured":"Greiffo FR, Viteri-Alvarez V, Frankenberger M et al (2020) CX3CR1-fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00460-2019","journal-title":"Eur Respir J"},{"issue":"2","key":"9157_CR57","first-page":"275","volume":"41","author":"A KOKUZAWA","year":"2023","unstructured":"Kokuzawa A, Nakamura J, Kamata Y et al (2023) Potential role of type I interferon\/IP-10 axis in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis [J]. Clin Exp Rheumatol 41(2):275\u2013284","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"9157_CR58","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","volume":"31","author":"J Wenzel","year":"2006","unstructured":"Wenzel J, Schmidt R, Proelss J et al (2006) Type I interferon-associated skin recruitment of CXCR3\u2009+\u2009lymphocytes in dermatomyositis. Clin Exp Dermatol 31(4):576\u201382","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"9157_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10067-017-3799-y","volume":"37","author":"Y PENG","year":"2018","unstructured":"Peng Y, Zhang S, Zhao Y et al (2018) Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis [J]. Clin Rheumatol 37(1):107\u2013115","journal-title":"Clin Rheumatol"},{"key":"9157_CR60","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134189","author":"N Seto","year":"2020","unstructured":"Seto N, Torres-Ruiz JJ, Carmona-Rivera C et al (2020) Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.134189","journal-title":"JCI Insight"},{"issue":"2","key":"9157_CR61","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/jcmm.14858","volume":"24","author":"S ZHANG","year":"2020","unstructured":"Zhang S, Jia X, Zhang Q et al (2020) Neutrophil extracellular traps activate lung fibroblast to induce polymyositis-related interstitial lung diseases via TLR9-miR-7-Smad2 pathway [J]. J Cell Mol Med 24(2):1658\u20131669","journal-title":"J Cell Mol Med"},{"key":"9157_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.628128","volume":"9","author":"L Liang","year":"2021","unstructured":"Liang L, Zhang YM, Shen YW et al (2021) Aberrantly expressed galectin-9 is involved in the immunopathogenesis of anti-MDA5-positive dermatomyositis-associated interstitial lung disease. Front Cell Dev Biol 9:628128","journal-title":"Front Cell Dev Biol"},{"key":"9157_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866087","volume":"13","author":"AS Galindo-Feria","year":"2022","unstructured":"Galindo-Feria AS, Notarnicola A, Lundberg IE et al (2022) Aminoacyl-tRNA synthetases: on anti-synthetase syndrome and beyond. Front Immunol 13:866087","journal-title":"Front Immunol"},{"issue":"5","key":"9157_CR64","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.4049\/jimmunol.1501902","volume":"197","author":"B Hervier","year":"2016","unstructured":"Hervier B, Perez M, Allenbach Y et al (2016) Involvement of NK cells and NKp30 pathway in antisynthetase syndrome. J Immunol 197(5):1621\u201330","journal-title":"J Immunol"},{"issue":"4","key":"9157_CR65","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/cdd.2009.197","volume":"17","author":"E Darrah","year":"2010","unstructured":"Darrah E, Rosen A (2010) Granzyme B cleavage of autoantigens in autoimmunity. Cell Death Differ 17(4):624\u201332","journal-title":"Cell Death Differ"},{"issue":"1","key":"9157_CR66","doi-asserted-by":"publisher","first-page":"22574","DOI":"10.1038\/s41598-021-01992-y","volume":"11","author":"S REMUZGO-MART\u00edNEZ","year":"2021","unstructured":"Remuzgo-Mart\u00ednez S, Atienza-Mateo B, Ocejo-Vinyals J G et al (2021) Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome [J]. Sci Rep 11(1):22574","journal-title":"Sci Rep"},{"issue":"1","key":"9157_CR67","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/art.41075","volume":"72","author":"GALINDO-FERIA A S","year":"2020","unstructured":"Galindo-Feria A S, Albrecht I, Fernandes-Cerqueira C et al (2020) Proinflammatory Histidyl-Transfer RNA Synthetase-Specific CD4\u2009+\u2009T Cells in the Blood and Lungs of Patients With Idiopathic Inflammatory Myopathies [J]. Arthritis Rheumatol 72(1):179\u2013191","journal-title":"Arthritis Rheumatol"},{"key":"9157_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804034","volume":"13","author":"L Zhu","year":"2022","unstructured":"Zhu L, Cao Z, Wang S et al (2022) Single-cell transcriptomics reveals peripheral immune responses in anti-synthetase syndrome-associated interstitial lung disease. Front Immunol 13:804034","journal-title":"Front Immunol"},{"key":"9157_CR69","doi-asserted-by":"publisher","first-page":"1652999","DOI":"10.3389\/fimmu.2025.1652999","volume":"16","author":"Y FAN","year":"2025","unstructured":"Fan Y, Zhang W (2025) Monocyte-driven IFN and TNF programs orchestrate inflammatory networks in antisynthetase syndrome-associated interstitial lung disease [J]. Front Immunol 16:1652999","journal-title":"Front Immunol"},{"issue":"9","key":"9157_CR70","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s10067-020-05013-7","volume":"39","author":"GL Behrens Pinto","year":"2020","unstructured":"Behrens Pinto GL, Carboni RCS, De Souza FHC et al (2020) A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome. Clin Rheumatol 39(9):2763\u201371","journal-title":"Clin Rheumatol"},{"issue":"178","key":"9157_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005580","volume":"5","author":"R Khandpur","year":"2013","unstructured":"Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A et al (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5(178):178ra40","journal-title":"Sci Transl Med"},{"issue":"3","key":"9157_CR72","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S2213-2600(24)00267-4","volume":"13","author":"S SEHGAL","year":"2025","unstructured":"Sehgal S, Patel A, Chatterjee S et al (2025) Idiopathic inflammatory myopathies related lung disease in adults [J]. Lancet Respir Med 13(3):272\u2013288","journal-title":"Lancet Respir Med"},{"key":"9157_CR73","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2018.12.040","volume":"397","author":"L Li","year":"2019","unstructured":"Li L, Wang H, Wang Q et al (2019) Myositis-specific autoantibodies in dermatomyositis\/polymyositis with interstitial lung disease. J Neurol Sci 397:123\u20138","journal-title":"J Neurol Sci"},{"issue":"1","key":"9157_CR74","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","volume":"51","author":"AH Opinc","year":"2021","unstructured":"Opinc AH, Makowska JS (2021) Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum 51(1):72\u201383","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"9157_CR75","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","volume":"11","author":"I MARIE","year":"2012","unstructured":"Marie I, Josse S, Decaux O et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome [J]. Autoimmun Rev 11(10):739\u2013745","journal-title":"Autoimmun Rev"},{"key":"9157_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8112013","author":"L Cavagna","year":"2019","unstructured":"Cavagna L, TRALLERO-ARAGU\u00e1S E, Meloni F et al (2019) Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8112013","journal-title":"J Clin Med"},{"key":"9157_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1482000","volume":"15","author":"CY Hsiao","year":"2024","unstructured":"Hsiao CY, Tseng SC, Hsu CY et al (2024) Clinical features of anti-SAE1 antibody-positive myositis and interstitial lung disease: a multicenter, retrospective study in Taiwan. Front Immunol 15:1482000","journal-title":"Front Immunol"},{"issue":"3","key":"9157_CR78","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/rheumatology\/keae232","volume":"64","author":"Y ZHANG","year":"2025","unstructured":"Zhang Y, Liu L, Duan X et al (2025) Longitudinal study of patients with anti-SAE antibody-positive dermatomyositis: a multicenter cohort study in China [J]. Rheumatology (Oxford) 64(3):1377\u20131385","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"9157_CR79","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1093\/rheumatology\/kead154","volume":"62","author":"J DEMORTIER","year":"2023","unstructured":"Demortier J, Vautier M, Chosidow O et al (2023) Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature [J]. Rheumatology (Oxford) 62(12):3932\u20133939","journal-title":"Rheumatology (Oxford)"},{"key":"9157_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106134","volume":"172","author":"X Xing","year":"2020","unstructured":"Xing X, Li A, Li C (2020) Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med 172:106134","journal-title":"Respir Med"},{"key":"9157_CR81","doi-asserted-by":"publisher","first-page":"106581","DOI":"10.1016\/j.rmed.2021.106581","volume":"187","author":"JEE A S","year":"2021","unstructured":"Jee A S, Parker M J S, Bleasel J F et al (2021) Diagnosis of myositis-associated interstitial lung disease: Utility of the myositis autoantibody line immunoassay [J]. Respir Med 187:106581","journal-title":"Respir Med"},{"issue":"1","key":"9157_CR82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-025-03520-z","volume":"27","author":"SS BAE","year":"2025","unstructured":"Bae SS, Shahbazian A, Wang J et al (2025) Plasma levels of adhesion molecules are elevated in dermatomyositis-interstitial lung disease and associated with low paraoxonase-1 activity [J]. Arthritis Res Ther 27(1):53","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"9157_CR83","first-page":"269","volume":"43","author":"E ZANATTA","year":"2025","unstructured":"Zanatta E, Moccaldi B (2025) Human epididymitis protein 4 as a biomarker of interstitial lung disease in patients with idiopathic inflammatory myopathies [J]. Clin Exp Rheumatol 43(2):269\u2013275","journal-title":"Clin Exp Rheumatol"},{"key":"9157_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109609","volume":"115","author":"F Sun","year":"2023","unstructured":"Sun F, Zhao J, Li Y et al (2023) Human epididymis protein 4 as a clinical biomarker in identifying interstitial lung disease in patients with idiopathic inflammatory myopathies. Int Immunopharmacol 115:109609","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"9157_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161436","volume":"11","author":"X Shu","year":"2016","unstructured":"Shu X, Peng Q, Lu X et al (2016) HMGB1 may be a biomarker for predicting the outcome in patients with polymyositis \/Dermatomyositis with interstitial lung disease. PLoS One 11(8):e0161436","journal-title":"PLoS One"},{"issue":"8","key":"9157_CR86","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1093\/rheumatology\/keaa819","volume":"60","author":"D Zhu","year":"2021","unstructured":"Zhu D, Qiao J, Tang S et al (2021) Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis. Rheumatology (Oxford) 60(8):3896\u2013903","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"9157_CR87","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s10067-019-04457-w","volume":"38","author":"L JIANG","year":"2019","unstructured":"Jiang L, Wang Y, Peng Q et al (2019) Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody [J]. Clin Rheumatol 38(6):1655\u20131663","journal-title":"Clin Rheumatol"},{"key":"9157_CR88","doi-asserted-by":"publisher","first-page":"1628928","DOI":"10.3389\/fimmu.2025.1628928","volume":"16","author":"W YUAN","year":"2025","unstructured":"Yuan W, Zhou X, Yang Y et al (2025) Associated factors in the development of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis [J]. Front Immunol 16:1628928","journal-title":"Front Immunol"},{"issue":"5","key":"9157_CR89","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jaad.2022.12.040","volume":"88","author":"K Shaw","year":"2023","unstructured":"Shaw K, Doudican N, Mishra A et al (2023) Differential gene expression in lesional skin may signify immune-mediated lung parenchymal damage in patients with dermatomyositis. J Am Acad Dermatol 88(5):1201\u20134","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"9157_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01226-3","volume":"20","author":"Y Lou","year":"2020","unstructured":"Lou Y, Zheng Y, Fan B et al (2020) Serum levels of interleukins and S100A8\/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease. BMC Pulm Med 20(1):196","journal-title":"BMC Pulm Med"},{"key":"9157_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152483","volume":"67","author":"C Li","year":"2024","unstructured":"Li C, Han Y, Li X et al (2024) Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis. Semin Arthritis Rheum 67:152483","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"9157_CR92","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/cei.13404","volume":"199","author":"LIANGL PENG Q L, ZHANG Y M","year":"2020","unstructured":"Peng Q L, Zhang Y M Liangl et al (2020) A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis [J]. Clin Exp Immunol 199(3):314\u2013325","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"9157_CR93","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-023-03243-z","volume":"26","author":"Y QIU","year":"2024","unstructured":"Qiu Y, Feng X, Liu C et al (2024) Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis [J]. Arthritis Res Ther 26(1):9","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"9157_CR94","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13075-025-03494-y","volume":"27","author":"X XU","year":"2025","unstructured":"Xu X, Qiu T, Sun K et al (2025) Integrated analysis of dermatomyositis reveals heterogeneous immune infiltration and interstitial lung disease-associated endotype [J]. Arthritis Res Ther 27(1):26","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"9157_CR95","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13023-024-03153-6","volume":"19","author":"Y SHI","year":"2024","unstructured":"Shi Y, You H, Liu C et al (2024) Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis [J]. Orphanet J Rare Dis 19(1):170","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"9157_CR96","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10067-015-3139-z","volume":"35","author":"Y XU","year":"2016","unstructured":"Xu Y, Yang C S, Li YJ et al (2016) Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis [J]. Clin Rheumatol 35(1):113\u2013116","journal-title":"Clin Rheumatol"},{"issue":"1","key":"9157_CR97","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13075-024-03415-5","volume":"26","author":"Y NIU","year":"2024","unstructured":"Niu Y, Liu S, Qiu Q et al (2024) Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease [J]. Arthritis Res Ther 26(1):184","journal-title":"Arthritis Res Ther"},{"key":"9157_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455944","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo Y, Liu H, Chen B et al (2024) Dysregulated CD38 expression on T cells was associated with rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 positive dermatomyositis. Front Immunol 15:1455944","journal-title":"Front Immunol"},{"key":"9157_CR99","doi-asserted-by":"publisher","first-page":"1321315","DOI":"10.3389\/fcimb.2023.1321315","volume":"13","author":"R QUINTERO-PUERTA T, LIRA-LUCIO J A,","year":"2023","unstructured":"Quintero-Puerta T, Lira-Lucio J A, Falf\u00e1n-Valencia R et al (2023) Lung microbiome alterations in patients with anti-Jo1 antisynthetase syndrome and interstitial lung disease [J]. Front Cell Infect Microbiol 13:1321315","journal-title":"Front Cell Infect Microbiol"},{"key":"9157_CR100","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H HOZUMI","year":"2016","unstructured":"Hozumi H, Fujisawa T, Nakashima R et al (2016) Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease [J]. Respir Med 121:91\u201399","journal-title":"Respir Med"},{"issue":"6","key":"9157_CR101","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s10067-024-06965-w","volume":"43","author":"M RIVERO-GALLEGOS D, MEJ\u00edA","year":"2024","unstructured":"Rivero-Gallegos D, Mej\u00eda M, Rocha-Gonz\u00e1lez Hi et al (2024) Association between anti-PL7 antibodies and increased fibrotic component in patients with antisynthetase syndrome and interstitial lung disease: a cross-sectional study [J]. Clin Rheumatol 43(6):1971\u20131978","journal-title":"Clin Rheumatol"},{"key":"9157_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1462242","volume":"15","author":"PD Burbelo","year":"2024","unstructured":"Burbelo PD, Huapaya JA, Khavandgar Z et al (2024) Quantification of autoantibodies using a luminescent profiling method in autoimmune interstitial lung disease. Front Immunol 15:1462242","journal-title":"Front Immunol"},{"issue":"5","key":"9157_CR103","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","volume":"29","author":"A NISHIOKA","year":"2019","unstructured":"Nishioka A, Tsunoda S, Abe T et al (2019) Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis [J]. Mod Rheumatol 29(5):814\u2013820","journal-title":"Mod Rheumatol"},{"issue":"1","key":"9157_CR104","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/keac229","volume":"62","author":"XU Y T","year":"2022","unstructured":"Xu Y T, Zhang Y M, Yang H X et al (2022) Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease [J]. Rheumatology (Oxford) 62(1):397\u2013406","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"9157_CR105","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/rheumatology\/key420","volume":"58","author":"S Takanashi","year":"2019","unstructured":"Takanashi S, Nishina N, Nakazawa M et al (2019) Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. Rheumatology (Oxford) 58(6):1034\u20139","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"9157_CR106","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/rheumatology\/kez571","volume":"59","author":"Y WANG","year":"2020","unstructured":"Wang Y, Chen S, Lin J et al (2020) Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease [J]. Rheumatology (Oxford) 59(8):2024\u20132029","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"9157_CR107","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.resinv.2019.10.004","volume":"58","author":"R Takei","year":"2020","unstructured":"Takei R, Yamano Y, Kataoka K et al (2020) Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease. Respir Investig 58(2):83\u201390","journal-title":"Respir Investig"},{"key":"9157_CR108","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf469","author":"S Matsuda","year":"2026","unstructured":"Matsuda S, Kotani T, Oe K et al (2026) Risk prediction model for relapse of anti-synthetase syndrome-associated interstitial lung disease in Japanese multicentre MYKO cohort study. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keaf469","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"9157_CR109","first-page":"1068","volume":"38","author":"W LYU","year":"2020","unstructured":"Lyu W, Zhou Y, Zhuang Y et al (2020) Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease [J]. Clin Exp Rheumatol 38(6):1068\u20131074","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"9157_CR110","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.resinv.2024.07.015","volume":"62","author":"M MODA","year":"2024","unstructured":"Moda M, Sumikawa H, Shintani R et al (2024) Natural history of indolent-anti-synthetase syndrome-associated interstitial lung disease [J]. Respir Investig 62(5):872\u2013878","journal-title":"Respir Investig"},{"issue":"6","key":"9157_CR111","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/crj.13616","volume":"17","author":"Y Li","year":"2023","unstructured":"Li Y, Liu X, Tian M et al (2023) Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease. Clin Respir J 17(6):507\u201315","journal-title":"Clin Respir J"},{"issue":"1","key":"9157_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1214-8","volume":"19","author":"Y Enomoto","year":"2017","unstructured":"Enomoto Y, Suzuki Y, Hozumi H et al (2017) Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther 19(1):9","journal-title":"Arthritis Res Ther"},{"key":"9157_CR113","doi-asserted-by":"publisher","first-page":"152350","DOI":"10.1016\/j.semarthrit.2023.152350","volume":"64","author":"X HE","year":"2024","unstructured":"He X, Ji J, Chen X et al (2024) Serum ferritin as a significant biomarker for patients with idiopathic inflammatory myopathy-associated interstitial lung disease: A systematic review and meta-analysis [J]. Semin Arthritis Rheum 64:152350","journal-title":"Semin Arthritis Rheum"},{"key":"9157_CR114","doi-asserted-by":"crossref","unstructured":"Zhang Y, Lai X, Li J et al (2026) Serum ferritin trajectories predict mortality risk in anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis: a longitudinal cohort study [J]. Eur Respir J","DOI":"10.1183\/13993003.01802-2025"},{"key":"9157_CR115","doi-asserted-by":"publisher","first-page":"155209","DOI":"10.1016\/j.cyto.2020.155209","volume":"135","author":"Y GAO","year":"2020","unstructured":"Gao Y, Zhao Q, Xie M et al (2020) Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease [J]. Cytokine 135:155209","journal-title":"Cytokine"},{"issue":"2","key":"9157_CR116","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/rheumatology\/kez301","volume":"59","author":"S MATSUDA","year":"2020","unstructured":"Matsuda S, Kotani T, Ishida T et al (2020) Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis\/dermatomyositis-interstitial lung disease [J]. Rheumatology (Oxford) 59(2):310\u2013318","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"9157_CR117","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/art.42785","volume":"76","author":"A FUKADA","year":"2024","unstructured":"Fukada A, Fujisawa T, Hozumi H et al (2024) Prognostic Role of Interferon-\u03bb3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease [J]. Arthritis Rheumatol 76(5):796\u2013805","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"9157_CR118","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","volume":"57","author":"S SATO","year":"2018","unstructured":"Sato S, Masui K, Nishina N et al (2018) Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients [J]. Rheumatology (Oxford) 57(7):1212\u20131221","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"9157_CR119","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3899\/jrheum.180825","volume":"46","author":"T FUJISAWA","year":"2019","unstructured":"Fujisawa T, Hozumi H, Yasui H et al (2019) Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease [J]. J Rheumatol 46(8):935\u2013942","journal-title":"J Rheumatol"},{"issue":"5","key":"9157_CR120","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s43657-023-00096-z","volume":"3","author":"R Zhang","year":"2023","unstructured":"Zhang R, Guo L, Sha J et al (2023) \u03b12,3-sialylation with fucosylation associated with more severe anti-MDA5 positive dermatomyositis induced by rapidly progressive interstitial lung disease. Phenomics 3(5):457\u201368","journal-title":"Phenomics"},{"issue":"3","key":"9157_CR121","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/rheumatology\/key341","volume":"58","author":"K WANG","year":"2019","unstructured":"Wang K, Zhao J, Chen Z et al (2019) CD4\u2009+\u2009CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease [J]. Rheumatology (Oxford) 58(3):511\u2013521","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"9157_CR122","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/art.42264","volume":"74","author":"Y Ye","year":"2022","unstructured":"Ye Y, Zhang X, Li T et al (2022) Two distinct immune cell signatures predict the clinical outcomes in patients with amyopathic dermatomyositis with interstitial lung disease. Arthritis Rheumatol 74(11):1822\u201332","journal-title":"Arthritis Rheumatol"},{"key":"9157_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.903887","volume":"9","author":"L Ye","year":"2022","unstructured":"Ye L, Zuo Y, Chen F et al (2022) Resistin expression is associated with interstitial lung disease in dermatomyositis. Front Med (Lausanne) 9:903887","journal-title":"Front Med (Lausanne)"},{"key":"9157_CR124","doi-asserted-by":"publisher","first-page":"885142","DOI":"10.3389\/fimmu.2022.885142","volume":"13","author":"L YE","year":"2022","unstructured":"Ye L, Zuo Y, Chen F et al (2022) Adrenomedullin Expression Is Associated With the Severity and Poor Prognosis of Interstitial Lung Disease in Dermatomyositis Patients [J]. Front Immunol 13:885142","journal-title":"Front Immunol"},{"issue":"4","key":"9157_CR125","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/art.41554","volume":"73","author":"M Nakazawa","year":"2021","unstructured":"Nakazawa M, Suzuki K, Takeshita M et al (2021) Distinct expression of coinhibitory molecules on alveolar T cells in patients with rheumatoid arthritis-associated and idiopathic inflammatory myopathy-associated interstitial lung disease. Arthritis Rheumatol 73(4):576\u201386","journal-title":"Arthritis Rheumatol"},{"key":"9157_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cells12010060","author":"E Ramos-Martinez","year":"2022","unstructured":"Ramos-Martinez E, VEGA-S\u00e1NCHEZ AE, P\u00e9REZ-RUBIO G et al (2022) Enhanced Activity of NLRP3 Inflammasome in the Lung of Patients with Anti-Synthetase Syndrome. Cells. https:\/\/doi.org\/10.3390\/cells12010060","journal-title":"Cells"},{"key":"9157_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.845988","volume":"13","author":"Y Zuo","year":"2022","unstructured":"Zuo Y, Ye L, Chen F et al (2022) Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome. Front Immunol 13:845988","journal-title":"Front Immunol"},{"issue":"2","key":"9157_CR128","first-page":"260","volume":"43","author":"W ZHANG","year":"2025","unstructured":"Zhang W, Huang G, Zheng S et al (2025) Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines [J]. Clin Exp Rheumatol 43(2):260\u2013268","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"9157_CR129","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/ard-2023-225284","volume":"83","author":"S Wu","year":"2024","unstructured":"Wu S, Xiao X, Zhang Y et al (2024) Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification. Ann Rheum Dis 83(6):775\u201386","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9157_CR130","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12931-025-03414-3","volume":"26","author":"L ZHU","year":"2025","unstructured":"Zhu L, Wu S, Zong C et al (2025) A serum biomarker-based index for predicting progressive pulmonary fibrosis in patients with anti-synthetase syndrome: the LOCCM index [J]. Respir Res 26(1):329","journal-title":"Respir Res"},{"issue":"10","key":"9157_CR131","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1093\/rheumatology\/keaf306","volume":"64","author":"X SHAN","year":"2025","unstructured":"Shan X, Huang Z, Wang G et al (2025) Predictive factors and clinical outcomes of progressive pulmonary fibrosis in anti-threonyl (PL7) positive anti-synthetase syndrome [J]. Rheumatology (Oxford) 64(10):5379\u20135387","journal-title":"Rheumatology (Oxford)"},{"key":"9157_CR132","doi-asserted-by":"publisher","first-page":"733599","DOI":"10.3389\/fmed.2021.733599","volume":"8","author":"Y LI","year":"2021","unstructured":"Li Y, Li Y, Wang Y et al (2021) A Clinical Risk Model to Predict Rapidly Progressive Interstitial Lung Disease Incidence in Dermatomyositis [J]. Front Med (Lausanne) 8:733599","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"9157_CR133","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.42308","volume":"75","author":"L XU","year":"2023","unstructured":"Xu L, You H, Wang L et al (2023) Identification of Three Different Phenotypes in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Patients: Implications for Prediction of Rapidly Progressive Interstitial Lung Disease [J]. Arthritis Rheumatol 75(4):609\u2013619","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"9157_CR134","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/joim.13607","volume":"293","author":"Q JIN","year":"2023","unstructured":"Jin Q, Fu L, Yang H et al (2023) Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis [J]. J Intern Med 293(4):494\u2013507","journal-title":"J Intern Med"},{"issue":"2","key":"9157_CR135","doi-asserted-by":"publisher","first-page":"304","DOI":"10.55563\/clinexprheumatol\/df2oc3","volume":"40","author":"Q YANG","year":"2022","unstructured":"Yang Q, Lyu K, Li J et al (2022) Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses [J]. Clin Exp Rheumatol 40(2):304\u2013308","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"9157_CR136","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.41566","volume":"73","author":"T GONO","year":"2021","unstructured":"Gono T, Masui K, Nishina N et al (2021) Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis\/Dermatomyositis-Associated Interstitial Lung Disease [J]. Arthritis Rheumatol 73(4):677\u2013686","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"9157_CR137","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","volume":"158","author":"X LIAN","year":"2020","unstructured":"Lian X, Zou J, Guo Q et al (2020) Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model [J]. Chest 158(4):1535\u20131545","journal-title":"Chest"},{"issue":"8","key":"9157_CR138","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.42861","volume":"76","author":"JOHNSON S R","year":"2024","unstructured":"Johnson S R, Bernstein E J, Bolster M B et al (2024) 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases [J]. Arthritis Rheumatol 76(8):1182\u20131200","journal-title":"Arthritis Rheumatol"},{"key":"9157_CR139","doi-asserted-by":"crossref","unstructured":"Antoniou K M, Distler O, Gheorghiu A M et al (2026) ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease [J]. Eur Respir J, 67(1)","DOI":"10.1183\/13993003.01973-2025"},{"issue":"5","key":"9157_CR140","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","volume":"61","author":"T OLDROYD A G S, LILLEKER J B, AMIN","year":"2022","unstructured":"Oldroyd A G S, Lilleker J B, Amin T et al (2022) British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy [J]. Rheumatology (Oxford) 61(5):1760\u20131768","journal-title":"Rheumatology (Oxford)"},{"key":"9157_CR141","doi-asserted-by":"publisher","first-page":"1568338","DOI":"10.3389\/fimmu.2025.1568338","volume":"16","author":"M TOKUNAGA","year":"2025","unstructured":"Tokunaga M, Nakai Y, Sato Y et al (2025) A pilot transcriptomic study of a novel multitargeted BRT regimen for anti-MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy [J]. Front Immunol 16:1568338","journal-title":"Front Immunol"},{"issue":"1","key":"9157_CR142","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"P MAHER T M, TUDOR V A, SAUNDERS","year":"2023","unstructured":"Maher T M, Tudor V A, Saunders P et al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial [J]. Lancet Respir Med 11(1):45\u201354","journal-title":"Lancet Respir Med"},{"key":"9157_CR143","doi-asserted-by":"publisher","first-page":"820163","DOI":"10.3389\/fimmu.2021.820163","volume":"12","author":"C HE","year":"2021","unstructured":"He C, Li W, Xie Q et al (2021) Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review [J]. Front Immunol 12:820163","journal-title":"Front Immunol"},{"issue":"3","key":"9157_CR144","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z CHEN","year":"2019","unstructured":"Chen Z, Wang X (2019) Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease [J]. N Engl J Med 381(3):291\u2013293","journal-title":"N Engl J Med"},{"issue":"12","key":"9157_CR145","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K KURASAWA","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y et al (2018) Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis [J]. Rheumatology (Oxford) 57(12):2114\u20132119","journal-title":"Rheumatology (Oxford)"},{"key":"9157_CR146","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002795","author":"T Ida","year":"2023","unstructured":"Ida T, Furuta S, Takayama A et al (2023) Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002795","journal-title":"RMD Open"},{"issue":"6","key":"9157_CR147","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3899\/jrheum.2024-1115","volume":"52","author":"A AGGARWAL","year":"2025","unstructured":"Aggarwal A, Almackenzie M (2025) Role of CD19 Chimeric Antigen Receptor T Cell Therapy in Idiopathic Inflammatory Myopathies [J]. J Rheumatol 52(6):532\u2013542","journal-title":"J Rheumatol"},{"key":"9157_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04185-6","author":"F M\u00fcLLER","year":"2026","unstructured":"M\u00fcLLER F, Hagen M, Wirsching A et al (2026) CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-04185-6","journal-title":"Nat Med"},{"issue":"8","key":"9157_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100676","volume":"6","author":"A PAR\u00edS-MU\u00f1OZ","year":"2025","unstructured":"PAR\u00edS-MU\u00f1OZ A, Alcobendas-Rueda RM, VERD\u00fa-S\u00e1NCHEZ C et al (2025) CD19 car-T cell therapy in a pediatric patient with MDA5(+) dermatomyositis and rapidly progressive interstitial lung disease. Med 6(8):100676","journal-title":"Med"},{"issue":"24","key":"9157_CR150","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"L PECHER A C, HENSEN","year":"2023","unstructured":"Pecher A C, Hensen L, Klein R et al (2023) CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome [J]. JAMA 329(24):2154\u20132162","journal-title":"JAMA"},{"issue":"9","key":"9157_CR151","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1093\/rheumatology\/keaf190","volume":"64","author":"I Haase","year":"2025","unstructured":"Haase I, Richter J, Holzer MT et al (2025) A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review. Rheumatology (Oxford) 64(9):5101\u20137","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"9157_CR152","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","volume":"31","author":"F M\u00fcLLER","year":"2025","unstructured":"M\u00fcLLER F, Wirsching A, Hagen M et al (2025) BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med 31(6):1793\u20137","journal-title":"Nat Med"},{"issue":"11","key":"9157_CR153","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1093\/rheumatology\/kead117","volume":"62","author":"Y Liu","year":"2023","unstructured":"Liu Y, Feng S, Liu X et al (2023) IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis. Rheumatology (Oxford) 62(11):3724\u201331","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"9157_CR154","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK et al (2020) Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8(5):453\u201360","journal-title":"Lancet Respir Med"},{"key":"9157_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.626953","volume":"8","author":"J Liang","year":"2021","unstructured":"Liang J, Cao H, Yang Y et al (2021) Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study. Front Med (Lausanne) 8:626953","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"9157_CR156","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01668-1","volume":"22","author":"V Cottin","year":"2021","unstructured":"Cottin V, Richeldi L, Rosas I et al (2021) Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res 22(1):84","journal-title":"Respir Res"},{"issue":"9","key":"9157_CR157","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 205(9):e18\u2013e47","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"9157_CR158","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M et al (2021) Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 9(5):476\u201386","journal-title":"Lancet Respir Med"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09157-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09157-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09157-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:02:58Z","timestamp":1775037778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09157-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":158,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9157"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09157-3","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}